Cargando…

375. Cryptococcal Antigenemia in Advanced HIV Infection

BACKGROUND: Diagnostic importance of asymptomatic cryptococcal antigenemia is being increasingly recognized in the last few years. Recently, WHO (World Health Organization) has recommended routine screening of CrAg (cryptococcal antigen) among PLHA with CD4 ≤100/mm(3), albeit this procedure is not y...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahuja, Jatin, Soneja, Manish, Wig, Naveet, Xess, Immaculata, Biswas, Ashutosh, Singh, Gagandeep, Vibha, Deepti, Nischal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809333/
http://dx.doi.org/10.1093/ofid/ofz360.448
_version_ 1783461961934045184
author Ahuja, Jatin
Soneja, Manish
Wig, Naveet
Xess, Immaculata
Biswas, Ashutosh
Singh, Gagandeep
Vibha, Deepti
Nischal, Neeraj
author_facet Ahuja, Jatin
Soneja, Manish
Wig, Naveet
Xess, Immaculata
Biswas, Ashutosh
Singh, Gagandeep
Vibha, Deepti
Nischal, Neeraj
author_sort Ahuja, Jatin
collection PubMed
description BACKGROUND: Diagnostic importance of asymptomatic cryptococcal antigenemia is being increasingly recognized in the last few years. Recently, WHO (World Health Organization) has recommended routine screening of CrAg (cryptococcal antigen) among PLHA with CD4 ≤100/mm(3), albeit this procedure is not yet adopted by many developing countries including India. METHODS: We conducted a prospective observational study in a large tertiary care center of North India, upon ethical clearance. Latex agglutination test was performed to assess serum CrAg levels, followed by the lumbar puncture for detection of CrAg levels in the CSF. We analyzed the prevalence and treatment outcomes of cryptococcal antigenemia among PLHA with CD4 ≤ 100 cells/mm(3). Detailed clinical examination was conducted, with follow-up of upto 3 months. Multivariate analysis was performed for the estimation of risk factors. RESULTS: The mean age (years) and BMI (kg/m(2)) of all the participants were 41.4 ± 11.2 and 22.1 ± 2.6, respectively. Notably, the mean CD4 count (cu.mm) at the time of recruitment was 62.3 ± 20.5. Noteworthy, 62 (60.8%) of the patients were ART naïve. We found 9.8% (n = 10) of the patients were positive for serum CrAg, and only 2.9% (n = 3) had clinical features of meningitis and 6.8% (n = 7) were asymptomatic (subclinical) CrAg positive. Strikingly, 3.9% (n = 4) of the asymptomatic cryptococcal antigenemia patients were also positive for CrAg in CSF, with 1.9% (n = 2) were only serum CrAg positive, and 1 patient was lost to follow-up (Graph 1). Multivariate analysis revealed that patients with long duration of HIV (P = 0.04), headache symptoms (P = 0.004) and possessing features of meningismus (P value=0.08) are more likely to be CrAg positive. Conversely, patients on fluconazole were protective against cryptococcal antigenemia (P = 0.1) as shown in Table 1. Overall mortality observed was 11.3% among advanced HIV patients. Moreover, mortality in CrAg-positive patients was 33.3% in comparison to CrAg-negative patients who had 9% (P = 0.06) in 3-months follow-up. CONCLUSION: Cryptococcal antigenemia is common (9.8%) among patients with CD4 count ≤100/mm(3) in India. Screening for CrAg should be made routine for PLHA with CD4 count ≤100/mm(3) and if required preemptive treatment to be given in this regard. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809333
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68093332019-10-28 375. Cryptococcal Antigenemia in Advanced HIV Infection Ahuja, Jatin Soneja, Manish Wig, Naveet Xess, Immaculata Biswas, Ashutosh Singh, Gagandeep Vibha, Deepti Nischal, Neeraj Open Forum Infect Dis Abstracts BACKGROUND: Diagnostic importance of asymptomatic cryptococcal antigenemia is being increasingly recognized in the last few years. Recently, WHO (World Health Organization) has recommended routine screening of CrAg (cryptococcal antigen) among PLHA with CD4 ≤100/mm(3), albeit this procedure is not yet adopted by many developing countries including India. METHODS: We conducted a prospective observational study in a large tertiary care center of North India, upon ethical clearance. Latex agglutination test was performed to assess serum CrAg levels, followed by the lumbar puncture for detection of CrAg levels in the CSF. We analyzed the prevalence and treatment outcomes of cryptococcal antigenemia among PLHA with CD4 ≤ 100 cells/mm(3). Detailed clinical examination was conducted, with follow-up of upto 3 months. Multivariate analysis was performed for the estimation of risk factors. RESULTS: The mean age (years) and BMI (kg/m(2)) of all the participants were 41.4 ± 11.2 and 22.1 ± 2.6, respectively. Notably, the mean CD4 count (cu.mm) at the time of recruitment was 62.3 ± 20.5. Noteworthy, 62 (60.8%) of the patients were ART naïve. We found 9.8% (n = 10) of the patients were positive for serum CrAg, and only 2.9% (n = 3) had clinical features of meningitis and 6.8% (n = 7) were asymptomatic (subclinical) CrAg positive. Strikingly, 3.9% (n = 4) of the asymptomatic cryptococcal antigenemia patients were also positive for CrAg in CSF, with 1.9% (n = 2) were only serum CrAg positive, and 1 patient was lost to follow-up (Graph 1). Multivariate analysis revealed that patients with long duration of HIV (P = 0.04), headache symptoms (P = 0.004) and possessing features of meningismus (P value=0.08) are more likely to be CrAg positive. Conversely, patients on fluconazole were protective against cryptococcal antigenemia (P = 0.1) as shown in Table 1. Overall mortality observed was 11.3% among advanced HIV patients. Moreover, mortality in CrAg-positive patients was 33.3% in comparison to CrAg-negative patients who had 9% (P = 0.06) in 3-months follow-up. CONCLUSION: Cryptococcal antigenemia is common (9.8%) among patients with CD4 count ≤100/mm(3) in India. Screening for CrAg should be made routine for PLHA with CD4 count ≤100/mm(3) and if required preemptive treatment to be given in this regard. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809333/ http://dx.doi.org/10.1093/ofid/ofz360.448 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ahuja, Jatin
Soneja, Manish
Wig, Naveet
Xess, Immaculata
Biswas, Ashutosh
Singh, Gagandeep
Vibha, Deepti
Nischal, Neeraj
375. Cryptococcal Antigenemia in Advanced HIV Infection
title 375. Cryptococcal Antigenemia in Advanced HIV Infection
title_full 375. Cryptococcal Antigenemia in Advanced HIV Infection
title_fullStr 375. Cryptococcal Antigenemia in Advanced HIV Infection
title_full_unstemmed 375. Cryptococcal Antigenemia in Advanced HIV Infection
title_short 375. Cryptococcal Antigenemia in Advanced HIV Infection
title_sort 375. cryptococcal antigenemia in advanced hiv infection
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809333/
http://dx.doi.org/10.1093/ofid/ofz360.448
work_keys_str_mv AT ahujajatin 375cryptococcalantigenemiainadvancedhivinfection
AT sonejamanish 375cryptococcalantigenemiainadvancedhivinfection
AT wignaveet 375cryptococcalantigenemiainadvancedhivinfection
AT xessimmaculata 375cryptococcalantigenemiainadvancedhivinfection
AT biswasashutosh 375cryptococcalantigenemiainadvancedhivinfection
AT singhgagandeep 375cryptococcalantigenemiainadvancedhivinfection
AT vibhadeepti 375cryptococcalantigenemiainadvancedhivinfection
AT nischalneeraj 375cryptococcalantigenemiainadvancedhivinfection